Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8311 to 8325 of 8906 results

  1. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Withdrawn guidance

  2. Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1059.

    Withdrawn guidance

  3. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    In November 2021, we withdrew this guidance because dapagliflozin (Forxiga) with insulin is no longer licensed for treating type 1 diabetes.

    Withdrawn guidance

  4. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Withdrawn guidance

  5. Taxanes for the treatment of breast cancer (TA6)

    This guidance has been replaced by NICE technology appraisal guidance 30 [Replaced by NICE guideline CG81].

    Withdrawn guidance

  6. Guidance on the use of patient-education models for diabetes (TA60)

    This guidance has been replaced by NICE guideline NG17.

    Withdrawn guidance

  7. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

    This guidance has been updated and replaced by NICE technology appraisal guidance 770.

    Withdrawn guidance

  8. Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

    This guidance has been updated and replaced by NICE guideline NG199.

    Withdrawn guidance

  9. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Withdrawn guidance

  10. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Withdrawn guidance

  11. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  12. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1119.

    Withdrawn guidance

  13. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Withdrawn guidance

  14. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Withdrawn guidance

  15. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.

    Withdrawn guidance